Figure_7.tif (3.12 MB)
Download file

Sorafenib augments the therapeutic efficacy of ACT by inhibiting STAT3 expression and downregulating immunosuppressive factors in tumor cells and tumor microenvironment.

Download (0 kB)
posted on 2014-10-15, 03:21 authored by Hui-Yen Chuang, Ya-Fang Chang, Ren-Shyan Liu, Jeng-Jong Hwang

Downregulation of immunosuppressive factors, including TGF-β, IL-10, CCL2/MCP-1 and VEGF, lowers the populations of both Tregs and MDSCs. Transferred CD8+ T cells show better activation and killing effects due to declined Tregs and MDSCs. Furthermore, more transferred CD8+ T cells accumulate in tumors and survive longer, so that enhanced therapeutic responses can be achieved.